^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G13D

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC (NCT05254184)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    01/24/2024
    Initiation :
    11/01/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (GO-005) (NCT03953235)
    Phase 1/2
    Gritstone bio, Inc.
    Completed
    Last update posted :
    09/13/2023
    Initiation :
    07/18/2019
    Primary completion :
    03/10/2023
    Completion :
    03/10/2023
    KRAS
    |
    KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS
    HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT03284502)
    Phase 1
    Hanmi Pharmaceutical Company Limited
    Active, not recruiting
    Last update posted :
    08/01/2023
    Initiation :
    05/22/2017
    Primary completion :
    09/30/2024
    Completion :
    12/31/2024
    KRAS • BRAF • NRAS • PI3K
    |
    EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13
    |
    Erbitux (cetuximab) • Cotellic (cobimetinib) • belvarafenib (RG6185)
    Milciclib in Combination With Gemcitabine in Advanced NSCLC (NCT05651269)
    Phase 2
    Tiziana Life Sciences LTD
    Not yet recruiting
    Last update posted :
    12/15/2022
    Initiation :
    03/15/2023
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13
    |
    gemcitabine • milciclib (TZLS-201)